Faculty Mentor

Dr. Elaine Vanterpool

Download

Download Full Text (1.0 MB)

Description

Leukemia is the cancer of the body’s blood-forming tissues, including the bone marrow and the lymphatic system. Mainly, leukemia effects the white blood cells. The malignancy known as leukemia damages the body's capacity to make healthy blood cells and starts in the bone marrow. White blood cells, which are essential to the immune system, are its main target. Leukemia disrupts normal blood function by causing an aberrant multiplication of immature blood cells, in contrast to other malignancies that create solid tumors. The disease is divided into various categories according to the particular blood cells impacted, and it can develop either quickly (acute leukemia) or slowly (chronic leukemia). An important gene that fights against this type of cancer is the VHL (Von Hippel-Lindau gene). Increased activity of hypoxia-inducible factors (HIFs), which support the survival and growth of aberrant blood cells, can result from VHL dysregulation. Leukemia may progress as a result of this disturbance of oxygen balance and cellular metabolism, especially when the milieu in the bone marrow becomes conducive to malignant transformation. Furthermore, changes or mutations in VHL may affect how leukemic cells react to chemotherapy, which could affect the course of treatment. The purpose of my research was to find the relation of a missense mutation in this specific gene and how it is related to the disease of Leukemia. This specific gene is found ink most parts of the body due to the fact that it not only defends leukemia but many other cancers as it is mainly tumor suppressor gene. It mainly defends against the Von Hippel-Lindau disease, which is a disease that causes tumors and cysts to develop in various organs in the body

Publication Date

4-1-2025

City

Huntsville

Disciplines

Biology

Comments

Marquise De Velde, Student Researcher

An analysis of VHL and its relation to Leukemia

Included in

Biology Commons

Share

 
COinS